In our study, we found that a high-sugar and high-fat diet with STZ treatment-induced T2DM with NAFLD in rats, and through immunofluorescence assay, RT-PCR, and WB, we showed that the levels of FAM134B expression decreased in the model group and that the levels of FAM134B expression increased significantly after JPXZF treatment, which was consistent with the trend in the LC3II/I ratio change. The gene discussed is RETREG1; the disease is metabolic dysfunction-associated steatotic liver disease.